Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS212 + JS111 in EGFR-Mutant Advanced NSCLC
NCT07518160Phase 2Recruiting
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of JS212, js111 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Apr 2026; status: recruiting.
02
Drugs
JS212js111
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07518160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518160.